REMS
Contraindicated in:
Use Cautiously in:
CV: asystole, bradycardia, heart block, QT interval prolongation, hypertension, syncope
Derm: BASAL/SQUAMOUS CELL CARCINOMA, MELANOMA
EENT: blurred vision, eye pain, macular edema
GI: ↑liver enzymes, diarrhea, HEPATOTOXICITY
Hemat: leukopenia, lymphopenia
MS: back pain
Neuro: headache, posterior reversible encephalopathy syndrome (pres), progressive multifocal leukoencephalopathy (pml), tumefactive MS
Resp: cough, ↓pulmonary function
Misc: hypersensitivity reactions (including angioedema), IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS), INFECTION (INCLUDING BACTERIAL, VIRAL AND FUNGAL), LYMPHOMA
Drug-drug:
Therapeutic Classification: anti-multiple sclerosis agents
Pharmacologic Classification: receptor modulators
Absorption: 93% absorbed following oral administration.
Distribution: Extensively distributed to body tissues; 86% of parent drug distributes into red blood cells; active metabolite uptake 17%.
Protein Binding: >99.7%.
Half-Life: 69 days.
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 12 mo* | 2 mo‡ |
*Time to steady state plasma concentrations, peak plasma concentrations after a single dose at 1216 hr.
‡Time for complete elimination.
NDC Code